Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 30Leukemia 15Burkitt Lymphoma 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Extranodal NK-T-Cell 4Leukemia, Biphenotypic, Acute 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphohistiocytosis, Hemophagocytic 2Epstein-Barr Virus Infections 2Down Syndrome 2Neoplasms 1Lymphoproliferative Disorders 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Immunoproliferative Disorders 1Drug-Related Side Effects and Adverse Reactions 1Blast Crisis 1

Interventions

pegaspargase 2Methylprednisolone 2Etoposide 2spartalizumab 1Tegafur 1Mitomycin 1Lenalidomide 1Epirubicin 1Doxorubicin 1Dexamethasone 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Epstein-Barr Virus Infections × pegaspargase × Clear all
NCT02912702 2016-09-23

L-DEP as an Initial Treatment for EBV-HLH

Beijing Friendship Hospital

Phase 3 Unknown
120 enrolled
Myeloid

Epstein-Barr Virus Infections, Lymphohistiocytosis, Hemophagocytic

NCT02631109 2016-08-04

L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis

Beijing Friendship Hospital

Phase 3 Unknown
120 enrolled
Myeloid

Epstein-Barr Virus Infections, Lymphohistiocytosis, Hemophagocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡